{
    "clinical_study": {
        "@rank": "125907", 
        "acronym": "repeat", 
        "arm_group": [
            {
                "arm_group_label": "XELOX adjuvant group", 
                "arm_group_type": "Active Comparator", 
                "description": "D2 resection\nXELOX (Drug: Capecitabine 1,000 mg/m\u00b2 twice daily. Film coated tablets of 500 mg. d1-14 q3w Drug: Oxaliplatin IV infusion, 130mg/m\u00b2 d1 q3w) 6 cycles"
            }, 
            {
                "arm_group_label": "XELOX neoadjuvant", 
                "arm_group_type": "Experimental", 
                "description": "XELOX (Drug: Capecitabine 1,000 mg/m\u00b2 twice daily. Film coated tablets of 500 mg. d1-14 q3w Drug: Oxaliplatin IV infusion, 130mg/m\u00b2 d1 q3w) 3 cycles chemotherapy before operation.\nD2 resection\nAfter operation:\nCR/PR: XELOX (Drug: Capecitabine 1,000 mg/m\u00b2 twice daily. Film coated tablets of 500 mg. d1-14 q3w Drug: Oxaliplatin IV infusion, 130mg/m\u00b2 d1 q3w) 3 cycles chemotherapy after operation. SD/PD:,ST(Drug: S-1\uff0c40-75mg twice daily. d1-14 q3w Drug: Paclitaxel IV infusion 135mg/m2 d1; q3w) 3 cycles chemotherapy after operation."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to demonstrate that capecitabine/oxaliplatin as perioperative\n      chemotherapy is superior or not to operation directly for locally advanced gastric cancer in\n      terms of 3 year disease-free survival (DFS) rate."
        }, 
        "brief_title": "Efficiency of XELOX Neoadjuvant Chemotherapy in Gastric Cancer", 
        "completion_date": {
            "#text": "December 2020", 
            "@type": "Anticipated"
        }, 
        "condition": "Gastric Cancer", 
        "condition_browse": {
            "mesh_term": "Stomach Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "The patients of gastric cancer have been divided into two parts in random.The test group\n      receive perioperative chemotherapy (XELOX) six cycles and the control group administrate the\n      same program after operation. The two groups have the same staging and eligibility\n      criteria.The 3 year disease-free survival (DFS) rate and 5 year overall survival (OS) rate\n      maybe the last evaluation standard."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Karnofsky performance status of \u226560 %.\n\n          -  Histologically confirmed gastric adenocarcinoma, staged pathologically or clinically,\n             stage cT2-4N+M0, and cT4N0M0.\n\n          -  Patients had to have adequate renal function (serum creatinine \u22641 times the upper\n             limit of normal [ULN]), hepatic function (total bilirubin \u22641\u00b75 times the ULN,\n             aspartate or alanine aminotransferase \u22642\u00b75 times the ULN, alkaline phosphatase \u22642\u00b75\n             times the ULN, Serum albumin \u226530g/L), and haematological function (absolute\n             neutrophil count \u22651\u00b75\u00d710\u2079/L and platelet count \u2265100\u00d710\u2079/L)\n\n        Exclusion Criteria:\n\n          -  Pregnant or lactating women.\n\n          -  According to the AJCC TMN 7.0, Any evidence of metastatic (TxNxM1) patients(including\n             presence of tumor cells in the ascites).\n\n          -  Sexually active males and females (of childbearing potential) unwilling to practice\n             contraception during the study.\n\n          -  Previous cytotoxic chemotherapy, radiotherapy or immunotherapy except\n             corticosteroids, for the currently treated gastric cancer.\n\n          -  Has uncontrolled epilepsy, central nervous system diseases or mental disorders of\n             history.\n\n          -  Clinically significant (i.e. active) cardiac disease e.g. symptomatic coronary artery\n             disease, New York Heart Association (NYHA) grade II or greater congestive heart\n             failure or serious cardiac arrhythmia requiring medication or myocardial infarction\n             within the last 12 months.\n\n          -  Lack of physical integrity of the upper gastrointestinal tract or those who have\n             malabsorption syndrome likely to influence absorption of capecitabine, or inability\n             to take oral medication.\n\n          -  Known peripheral neuropathy \u2265 CTCAEv3 grade 1 (Common Terminology for Adverse\n             Events). Absence of deep tendon reflexes as the sole neurologic abnormality does not\n             render the patient ineligible.\n\n          -  Organ allografts requiring immunosuppressive therapy.\n\n          -  Serious uncontrolled intercurrent infections or other serious uncontrolled\n             concomitant disease.\n\n          -  Moderate or severe renal impairment [creatinine clearance equal to or below 50 ml/min\n             (calculated according to Cockroft and Gault)], or serum creatinine > 1.5 x upper\n             limit of normal (ULN).\n\n          -  Any of the following laboratory values:\n\n               -  Absolute neutrophil count (ANC) < 1.5 x 109/L\n\n               -  Platelet count < 100 x 109/L\n\n               -  Total bilirubin > 1.5 x ULN\n\n               -  ALAT, ASAT > 2.5 x ULN\n\n               -  Alkaline phosphatase > 2.5 x ULN.\n\n          -  Prior unanticipated severe reaction to fluoropyrimidine therapy (with or without\n             documented dihydropyrimidine dehydrogenase (DPD) deficiency) or patients with known\n             DPD deficiency.\n\n          -  Hypersensitivity to platinum compounds or any of the components of the study\n             medications.\n\n          -  Received any investigational drug or agent/procedure, i.e. participation in another\n             trial, within 4 weeks before randomization.\n\n        The above information is not intended to contain all considerations relevant to a\n        patient's potential participation in a clinical trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 5, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01665274", 
            "org_study_id": "GCPCT1205/repeat"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "XELOX adjuvant group", 
                    "XELOX neoadjuvant"
                ], 
                "description": "Capecitabine 1,000 mg/m\u00b2 twice daily, d1-14, q3w", 
                "intervention_name": "Capecitabine", 
                "intervention_type": "Drug", 
                "other_name": "xeloda"
            }, 
            {
                "arm_group_label": [
                    "XELOX adjuvant group", 
                    "XELOX neoadjuvant"
                ], 
                "description": "Oxaliplatin IV infusion, 130mg/m\u00b2 d1, q3w", 
                "intervention_name": "Oxaliplatin", 
                "intervention_type": "Drug", 
                "other_name": "eloxatin"
            }, 
            {
                "arm_group_label": [
                    "XELOX adjuvant group", 
                    "XELOX neoadjuvant"
                ], 
                "description": "D2 resection", 
                "intervention_name": "D2 resection", 
                "intervention_type": "Procedure", 
                "other_name": "D2 resection"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Oxaliplatin", 
                "Capecitabine", 
                "Fluorouracil"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "xelox", 
            "advanced gastric cancer"
        ], 
        "lastchanged_date": "December 19, 2013", 
        "location": {
            "contact": {
                "email": "xyw801@163.com", 
                "last_name": "Yingwei Xue, Phd, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Ha er Bin", 
                    "country": "China", 
                    "state": "Heilongjiang"
                }, 
                "name": "Harbin Medical University Cancer Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Single Center Controlled Study of Perioperative Chemotherapy of Oxaliplatin Combined With Capecitabine (XELOX) Versus XELOX as Post-operative Chemotherapy in Advanced Gastric Adenocarcinoma With D2 Dissection", 
        "overall_contact": {
            "email": "xyw801@163.com", 
            "last_name": "Yingwei Xue, Phd, MD"
        }, 
        "overall_official": {
            "affiliation": "Harbin Medical University", 
            "last_name": "Yingwei Xue, Phd, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "3-year DFS", 
            "safety_issue": "No", 
            "time_frame": "3 years after surgery"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01665274"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Harbin Medical University", 
            "investigator_full_name": "Yingwei Xue", 
            "investigator_title": "Chief of Gastrointestinal Surgery", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "From date of randomization until the end of the study, assessed up to 5 years"
            }, 
            {
                "measure": "response rate", 
                "safety_issue": "No", 
                "time_frame": "evaluate after the end of neoadjuvant chemotherapy ie within 1 weeks after the neoadjuvant therapy"
            }, 
            {
                "measure": "R0 resection rate", 
                "safety_issue": "No", 
                "time_frame": "after the pathological examination of resected speciments ie within 1 month after the operation"
            }, 
            {
                "measure": "overall survival", 
                "safety_issue": "No", 
                "time_frame": "5 years after surgery"
            }
        ], 
        "source": "Harbin Medical University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Harbin Medical University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}